VAXIL

VAXIL BIO THERAPEUTICS

OCTOBER 2020

DIRECTING IMMUNITY DIRECTLY

Forward-looking statements

The information contained in this presentation is provided by Vaxil Bio Ltd. (“Vaxil”) for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Vaxil or other financial products. The information contained herein is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. The views, opinions and advice provided in this presentation reflect those of the individual presenters, and are provided for information purposes only. The presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of VaxilL nor its directors, officers, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation. Except for statements of historical fact, this presentation contains certain “ forward-looking information” within the meaning of applicable securities laws. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements, including, among others, Vaxil’s future growth and development, the proposed plans of any of VAXIL’s equity holdings, as well as those risk factors identified in Vaxil’s Filing Statement and other disclosure documents available at www.sedar.com under VAXIL’s name. Vaxil undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. This presentation does not constitute an offer of shares for sale in the United States or to any person that is, or is acting for the account or benefit of, any U.S. person (as defined in Regulation S under the United States Securities Act of 1933, as amended (the “Securities Act”) (“U.S. Person”), or in any other jurisdiction in which such an offer would be illegal. Vaxil’s shares have not been and will not be registered under the Securities Act.

Executive Summary

Vaxil is an Israeli biotechnology company developing novel immunotherapies including neoantigen-like signal peptides and antibodies to treat cancer and infectious diseases. Our experienced board and scientific team have access to world class medical centers and academia.

Leading platforms:

COVID- 19 Vaccine Candidate (Corvax^{tm})

- Successful COVID-19 pre-clinical work continues after potential Vaccine discovered and patents filed (3/20)
- Successful pre-clinical completed (9/20)
  - Immune response in vitro
- Path to clinical trial within 9-12 months

Oncology

- Phase 1/2a: multiple myeloma (US/EU orphan)
- High immunogenicity
- Robust immune response
- Specific to tumor cells
- No immune tolerance
- Bypasses tumor escape
- In-licensed P-EsBP polymer

Vaxil Team

David Goren, MBA
CEO and Chairman

- Head, Pfizer Worldwide Strategy and BD
- CEO, Pfizer Israel
- President, AstraZeneca Israel
- VP Digital Health Strategy

Gadi Levin, CPA, MBA
CFO and Director

- CFO, LabStyle Innovations Ltd
- CFO, BriaCell Therapeutics Corp.
- VP / CFO of 2 investment houses

Yuval Avnir, PhD, MA
Head of R&D

- Research Fellow, Dana-Farber Cancer Institute
- Head, Scientific Equipment Center, Bar Ilan U Faculty of Medicine (Galilee)

Riva Kovjazin, MD, PhD
Senior Scientist

- Project leader, Center for Clinical Immunology
- Senior scientist at XTL Biopharmaceutical

Vaxil Team

Ari S. Kellen, MD, MBA, Director

- Strategic advisor and investor to early-stage innovative healthcare companies
- Director, Theraclion
- Senior partner, McKinsey & Co.
- EVP and GM, Bausch & Lomb US
- Advisory board, BioNanoSim (BNS)

Shawn Langer, MD, Director

- Senior partner, McKinsey & Co.
- Portfolio manager, BHMS Investments

Ronny Pinkus, PhD, CMC

- VP Mfg & Operations, Moebius Medical
- Head Analytical, InSight Biopharmaceuticals

Rivka Zaibel, Regulatory & QA

- President, ADRES, VP RA/QA, BTG

Beth Leffel, PhD, MPH, PreClinical

- PharmAthene, NBACC, USAMRIID

Financial Summary

(updated September 30, 2020)

Market Cap

- CAD$13.6 M

Share price

- CAD$0.13

Cap Table

- Shares: 104.5 M
  - Warrants: 21.4 M (exercise price CAD$0.10)
  - Options: 6.6 M (avg exercise price CAD$0.10)

Trading History

- 2016: RTO into Canadian company (TSX.V)
- 2012: RTO by Vaxil on TASE
- 2011: Listed on TASE

Funds Raised (last 4 yrs) primarily from individuals

- 2020: CAD$1.4 million (warrant exercises)
- 2020: CAD$0.13 million (debentures)
- 2018: CAD$1.8 million (private placement)
- 2016: CAD$2.6 million (private placement)

Pipeline


Antigen Mining
VaxHit™ Proprietary Algorithm
Immune validation
Preclinical development
Clinical
ID
Tuberculosis
COVID-19 Vaccine
Other candidates
Oncology
MUC1-SP
Additional SPs
P-ESBP
mAb program

In Brief

01 Targeting COVID-19 (infectious disease) and solid tumors

02 VaxHit™ target ID for signal peptides and mAbs

03 Clinical stage immunotherapy

04 5 Patent families

05 Successful Phase 1/2a multiple myeloma clinical trial

06 Orphan designation for multiple myeloma (FDA / EMA)

07 P-ESBP In-licensing

08 VXL traded on TSXV

Signal Peptide Characteristics

Characteristics

Conserved short sequences

Dense number of epitopes
- Wide HLA-subclasses
- Cellular / humoral response

Specific to tumor cells

HLA-independent presentation

Vaxil Advantage

No antigen loss Broad population

Very high immunogenicity
- Universal – wide population
- Robust immune response

Neoantigen
- No immune tolerance
- Safety profile

Bypasses tumor escape

Universal Neoantigen

VAXIL
VAXIL BIO THERAPEUTICS

IP Portfolio



Applying Signal Peptide Platform to COVID-19

- Proprietary VaxHit™ tool identified signal peptides in SARS-CoV-2 (COVID-19) genome with high immunogenic potential
- Unique approach: Complete immune response
    - Cellular (T cell) AND humoral (antibodies)
    - Targeting infected cells, not virus
- Not susceptible to viral escape due to mutations
- Not prone to resurge due to protein mutations
- Potential for immunity preventing other outbreaks and therapeutic effects
- Efficiently manufactured and scaled (scale-up cost, simplicity)

CORVAX™ - VAXIL's COVID-19 VACCINE CANDIDATE

Achievement to Date

- Candidate/s discovered using proprietary VaxHit™ tool
- IP secured
- Preclinical efficacy experiments successfully demonstrated immunogenicity
    - ex vivo and in vivo immune response and functional assays
- Successfully established that CorVax™
    - demonstrates a favorable immune response in healthy blood cells
    - demonstrates a favorable immune response in animals

Next Steps

- Pre-clinical "challenge" in vivo experiment*
- Initiate GMP production, formulation including stability and solubility testing
- Secure IND regulatory pathway with gap analysis
- Tox, pre-IND and IND submission
- Phase I/IIa study

* In a "challenge" experiment animals are injected with the experimental vaccine followed by exposure to COVID-19. The experiment attempts to demonstrate that the animals who were vaccinated have a better result (i.e., are less sick).

CorVax™ Pre Clinical Experiments

In Vitro Immunogenicity:

Aim: Establish *CorVax™* immunogenicity by assessing T cell proliferation.

Method: Healthy donor peripheral blood mononuclear cells (PBMCs) stimulated by peptide-loaded autologous dendritic cells.

Results: T cell proliferation was observed by flow cytometry for all candidate signal peptides, to varying degrees, compared to unstimulated cells.

In Vivo Immunogenicity:

Aim: Establish *CorVax™* immunogenicity in an animal model by assessing antibody and T cell response.

Method: Two mice strains vaccinated with 3 weekly CorVax™ injections.

Results: Immune response was observed when analyzing results from ELISA, ELISpot, and restimulation assays.

VAXIL Planned Milestones

Timeline	Q4 ‘20	Q1 ‘21	Q2 ‘21	H2 ‘21+
COVID-19	Preclinical studies	GMP Production, Formulation, Tox & pre-IND / IND	Phase I/IIa*, Optimization	
Oncology	Peptide and polymer manufacturing	Solid Tumor preclinical experiments	Solid Tumor Anti-metastatic readout, formulation, optimization, Ph I prep (pre-IND)	

* subject to regulatory considerations due to COVID situation

Thank You

David Goren, CEO, david@vaxil-bio.com, +972 52 720 6000

Gadi Levin, CFO, gadi@vaxil-bio.com, +972 54 642 0352